{"id":59526,"date":"2024-06-13T19:05:21","date_gmt":"2024-06-13T17:05:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/"},"modified":"2024-06-13T19:05:21","modified_gmt":"2024-06-13T17:05:21","slug":"asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/","title":{"rendered":"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–#ASCO2024<\/a>–Brenus Pharma, French biotech developing its proprietary discovery platform: \u201cStimulated-Tumor-Cell\u201d (STC), has presented the study design of \u201cBreAK-CRC\u201d First-in-human of STC-1010, Brenus\u2019 lead candidate, during ASCO<\/a> annual meeting (31st<\/sup> May \u2013 4th<\/sup> June 2024) – Trials in Progress poster session,<\/i> in Chicago.<\/p>\n

<\/a>
<\/a><\/p>\n

\nPoster here<\/a>. | Benoit You et al.<\/a> Journal of Clinical Oncology<\/i> 42<\/b>, TPS3635-TPS3635(2024). DOI:10.1200\/JCO.2024.42.16_suppl.TPS3635<\/a>
Authors information\u2019s: here<\/a>.<\/p>\n

\nBased on STC-1010\u2019 robust preclinical package in vivo, in ovo, ex vivo<\/i>, BreAK-CRC study will be launched in 9 oncology early phase centers (EU, US) with expert investigators in immunotherapy:<\/p>\n

\n\u201cCancer vaccines continue to show promising clinical results in solid tumors. STC-1010, is a new immunotherapeutic approach based on cancer vaccine mechanism of action for colorectal cancer patients. In that, \u201cBreAK-CRC\u201d Study is eagerly expected. CRC is still challenging as current immunotherapies were found only active in dMMR\/MSI-H \u201chot\u201d CRC. For the pMMR\/MSS population, representing 95% of patients with CRC, there is an important medical need for drugs likely to heat up \u201ccold\u201d tumors and have a real impact for the patient.\u201d<\/i> Fran\u00e7ois Ghiringhelli (M.D,PhD) Director of early clinical unit CLIPP2 and BreAK-CRC study coordinator, Centre Georges-Fran\u00e7ois Leclerc<\/a>, University of Burgundy<\/a>, Dijon, France.<\/p>\n

\nBreAK-CRC trial protocol has been reviewed in pre-submission meeting with the <\/i>French National Health Authority<\/i><\/a>. The submission of the CTA through the <\/i>clinical trial information system of the European union<\/i><\/a> is ongoing.<\/i><\/p>\n

\nThe Phase I\/IIA clinical trial, aims to evaluate the safety and efficacy of STC-1010 in patients with unresectable advanced or metastatic colorectal cancer, 2nd<\/sup> cause of cancer mortality worldwide.<\/p>\n

\nThe Phase I will assess the tolerability of two dose levels of STC-1010, combined with low-dose immunostimulants and standard of care chemotherapy (SoC). The Phase IIA will enroll patients to further evaluate the treatment’s efficacy, particularly focusing on 12-month non-progression rate.<\/p>\n

\nExploratory analysis will evaluate the immune response and the ctDNA dynamic.<\/p>\n

\nClinical Partner<\/a><\/p>\n

\nAbout Brenus Pharma:<\/b><\/p>\n

\nBrenus Pharma developing a pioneering discovery platform, Stimulated-Tumor-Cell (STC), leading the way of a new generation of active immunotherapies against cancer.<\/p>\n

\nSTC Platform mimics patients’ relapsing conditions in vitro<\/i> to educate the patient\u2019s immune system against tumor evolution and mechanisms of relapse. The STCs will educate the immune system to 200+ specific targets of interest, validated by multi-omics analysis and patient biopsies databases.<\/p>\n

Contacts<\/b> <\/p>\n

\nBRUN Marion
\n
contact@brenus-pharma.com<\/a> | Follow us on LinkedIn<\/a> | Website<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–#ASCO2024–Brenus Pharma, French biotech developing its proprietary discovery platform: \u201cStimulated-Tumor-Cell\u201d (STC), has presented the study design of \u201cBreAK-CRC\u201d First-in-human of STC-1010, Brenus\u2019 lead candidate, during ASCO annual meeting (31st May \u2013 4th June 2024) – Trials in Progress poster session, in Chicago. Poster here. | Benoit You et al. Journal of Clinical Oncology … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59526","6":"format-standard","7":"category-industry"},"yoast_head":"\nASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France–(BUSINESS WIRE)–#ASCO2024–Brenus Pharma, French biotech developing its proprietary discovery platform: \u201cStimulated-Tumor-Cell\u201d (STC), has presented the study design of \u201cBreAK-CRC\u201d First-in-human of STC-1010, Brenus\u2019 lead candidate, during ASCO annual meeting (31st May \u2013 4th June 2024) – Trials in Progress poster session, in Chicago. Poster here. | Benoit You et al. Journal of Clinical Oncology ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-13T17:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240613547215\/en\/2159431\/22\/Logo_Brenus_Blue.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\\\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC\",\"datePublished\":\"2024-06-13T17:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/\"},\"wordCount\":416,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240613547215\\\/en\\\/2159431\\\/22\\\/Logo_Brenus_Blue.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/\",\"name\":\"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\\\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240613547215\\\/en\\\/2159431\\\/22\\\/Logo_Brenus_Blue.jpg\",\"datePublished\":\"2024-06-13T17:05:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240613547215\\\/en\\\/2159431\\\/22\\\/Logo_Brenus_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240613547215\\\/en\\\/2159431\\\/22\\\/Logo_Brenus_Blue.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\\\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/","og_locale":"en_US","og_type":"article","og_title":"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC - Pharma Trend","og_description":"LYON, France–(BUSINESS WIRE)–#ASCO2024–Brenus Pharma, French biotech developing its proprietary discovery platform: \u201cStimulated-Tumor-Cell\u201d (STC), has presented the study design of \u201cBreAK-CRC\u201d First-in-human of STC-1010, Brenus\u2019 lead candidate, during ASCO annual meeting (31st May \u2013 4th June 2024) – Trials in Progress poster session, in Chicago. Poster here. | Benoit You et al. Journal of Clinical Oncology ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/","og_site_name":"Pharma Trend","article_published_time":"2024-06-13T17:05:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240613547215\/en\/2159431\/22\/Logo_Brenus_Blue.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC","datePublished":"2024-06-13T17:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/"},"wordCount":416,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240613547215\/en\/2159431\/22\/Logo_Brenus_Blue.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/","url":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/","name":"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240613547215\/en\/2159431\/22\/Logo_Brenus_Blue.jpg","datePublished":"2024-06-13T17:05:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240613547215\/en\/2159431\/22\/Logo_Brenus_Blue.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240613547215\/en\/2159431\/22\/Logo_Brenus_Blue.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/asco-2024-brenus-pharma-presented-break-crc-first-in-human-fih-phase-i-iia-trial-of-stc-1010-a-next-generation-cancer-vaccine-targeting-mcrc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ASCO 2024: Brenus Pharma Presented \u201cBreAK-CRC\u201d First-in-human (FIH) Phase I\/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59526"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59526\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}